CN119684295A - 用于治疗疾病的双环化合物及其用途 - Google Patents
用于治疗疾病的双环化合物及其用途 Download PDFInfo
- Publication number
- CN119684295A CN119684295A CN202411623883.1A CN202411623883A CN119684295A CN 119684295 A CN119684295 A CN 119684295A CN 202411623883 A CN202411623883 A CN 202411623883A CN 119684295 A CN119684295 A CN 119684295A
- Authority
- CN
- China
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- mmol
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063108660P | 2020-11-02 | 2020-11-02 | |
| US63/108,660 | 2020-11-02 | ||
| CN202180079749.8A CN116568301A (zh) | 2020-11-02 | 2021-11-01 | 用于治疗疾病的双环化合物及其用途 |
| PCT/US2021/057563 WO2022094400A1 (en) | 2020-11-02 | 2021-11-01 | Bicyclic compounds and uses thereof for the treatment of diseases |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180079749.8A Division CN116568301A (zh) | 2020-11-02 | 2021-11-01 | 用于治疗疾病的双环化合物及其用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN119684295A true CN119684295A (zh) | 2025-03-25 |
Family
ID=81384389
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202411623883.1A Pending CN119684295A (zh) | 2020-11-02 | 2021-11-01 | 用于治疗疾病的双环化合物及其用途 |
| CN202180079749.8A Pending CN116568301A (zh) | 2020-11-02 | 2021-11-01 | 用于治疗疾病的双环化合物及其用途 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180079749.8A Pending CN116568301A (zh) | 2020-11-02 | 2021-11-01 | 用于治疗疾病的双环化合物及其用途 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240025903A1 (https=) |
| EP (1) | EP4236944A4 (https=) |
| JP (1) | JP2023550543A (https=) |
| KR (1) | KR20230104191A (https=) |
| CN (2) | CN119684295A (https=) |
| AR (1) | AR124637A1 (https=) |
| AU (1) | AU2021371026A1 (https=) |
| CA (1) | CA3196582A1 (https=) |
| CL (2) | CL2023001195A1 (https=) |
| IL (1) | IL302465A (https=) |
| MX (1) | MX2023004942A (https=) |
| WO (1) | WO2022094400A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240121239A (ko) * | 2021-12-17 | 2024-08-08 | 아티라 파마, 인코포레이티드 | 질환 치료를 위한 이환식 화합물의 용도 |
| EP4518864A1 (en) * | 2022-05-04 | 2025-03-12 | Athira Pharma, Inc. | Methods of treating neuropathies |
| JP2025515045A (ja) * | 2022-05-04 | 2025-05-13 | アティラ・ファーマ・インコーポレイテッド | 神経炎症病態を治療する方法 |
| EP4618996A1 (en) | 2022-11-18 | 2025-09-24 | Athira Pharma, Inc. | Methods of treating inflammatory conditions |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6184223B1 (en) * | 1995-10-27 | 2001-02-06 | Molecumetics Ltd. | Reverse-turn mimetics and methods relating thereto |
| AU2003284120A1 (en) * | 2002-10-17 | 2004-05-04 | Myriad Genetics, Inc. | Reverse-turn mimetics and composition and methods relating thereto |
| US7192976B2 (en) * | 2002-12-21 | 2007-03-20 | Angion Biomedica Corporation | Small molecule modulators of hepatocyte growth factor (scatter factor) activity |
| AU2005289560A1 (en) * | 2004-09-28 | 2006-04-06 | Angion Biomedica Corp. | Small molecule modulators of cytokine activity |
| US7879898B1 (en) * | 2006-02-14 | 2011-02-01 | Angion Biomedica Corp. | Hepatocyte growth factor pathway activators in chronic obstructive pulmonary disease |
| EP1947085A1 (en) * | 2007-01-19 | 2008-07-23 | Laboratorios del Dr. Esteve S.A. | Substituted indole sulfonamide compounds, their preparation and use as medicaments |
| CN102186853A (zh) * | 2008-10-14 | 2011-09-14 | 株式会社棱镜生物实验室 | 治疗癌症α-螺旋模拟物 |
| WO2014025832A1 (en) * | 2012-08-06 | 2014-02-13 | University Of Southern California | Wnt modulators for the protection, mitigation and treatment of radiation injury |
| WO2017047762A1 (ja) * | 2015-09-18 | 2017-03-23 | 国立大学法人鳥取大学 | 低分子化合物による癌と線維化の抑制と再生促進の効果 |
-
2021
- 2021-11-01 CN CN202411623883.1A patent/CN119684295A/zh active Pending
- 2021-11-01 MX MX2023004942A patent/MX2023004942A/es unknown
- 2021-11-01 EP EP21887720.7A patent/EP4236944A4/en active Pending
- 2021-11-01 AR ARP210103033A patent/AR124637A1/es unknown
- 2021-11-01 WO PCT/US2021/057563 patent/WO2022094400A1/en not_active Ceased
- 2021-11-01 US US18/032,918 patent/US20240025903A1/en active Pending
- 2021-11-01 IL IL302465A patent/IL302465A/en unknown
- 2021-11-01 CN CN202180079749.8A patent/CN116568301A/zh active Pending
- 2021-11-01 KR KR1020237018061A patent/KR20230104191A/ko active Pending
- 2021-11-01 CA CA3196582A patent/CA3196582A1/en active Pending
- 2021-11-01 JP JP2023551946A patent/JP2023550543A/ja active Pending
- 2021-11-01 AU AU2021371026A patent/AU2021371026A1/en active Pending
-
2023
- 2023-04-26 CL CL2023001195A patent/CL2023001195A1/es unknown
-
2024
- 2024-02-02 CL CL2024000340A patent/CL2024000340A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4236944A4 (en) | 2024-09-04 |
| TW202233622A (zh) | 2022-09-01 |
| US20240025903A1 (en) | 2024-01-25 |
| WO2022094400A1 (en) | 2022-05-05 |
| MX2023004942A (es) | 2023-07-06 |
| EP4236944A1 (en) | 2023-09-06 |
| JP2023550543A (ja) | 2023-12-01 |
| CA3196582A1 (en) | 2022-05-05 |
| AR124637A1 (es) | 2023-04-19 |
| CN116568301A (zh) | 2023-08-08 |
| CL2023001195A1 (es) | 2023-10-20 |
| AU2021371026A9 (en) | 2024-04-18 |
| KR20230104191A (ko) | 2023-07-07 |
| IL302465A (en) | 2023-06-01 |
| CL2024000340A1 (es) | 2024-08-16 |
| AU2021371026A1 (en) | 2023-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN119684295A (zh) | 用于治疗疾病的双环化合物及其用途 | |
| CN110156813A (zh) | 作为trk抑制剂的杂环化合物 | |
| KR20240121239A (ko) | 질환 치료를 위한 이환식 화합물의 용도 | |
| CN119156217A (zh) | 治疗神经炎症性病状的方法 | |
| EP4598907A1 (en) | Phenyl oxy amide kinase inhibitors | |
| CN118382441A (zh) | 双环化合物用于治疗疾病的用途 | |
| EP4518866A1 (en) | Methods of treating fibrosis | |
| TWI918751B (zh) | 用於治療疾病之雙環化合物及其用途 | |
| HK40122844A (zh) | 用於治疗疾病的双环化合物及其用途 | |
| HK40097563A (zh) | 用於治疗疾病的双环化合物及其用途 | |
| EA049703B1 (ru) | Бициклические соединения и их применение для лечения заболеваний | |
| CN119300834A (zh) | 治疗神经病变的方法 | |
| HK40113746A (zh) | 双环化合物用於治疗疾病的用途 | |
| EA050745B1 (ru) | Применение бициклических соединений для лечения заболеваний | |
| WO2025250930A1 (en) | Hdac6 inhibitors and method of their use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40122844 Country of ref document: HK |
|
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Country or region after: U.S.A. Address after: Washington State Applicant after: Leonard Bio Pharmaceuticals Co., Ltd. Address before: Washington State Applicant before: Yasina Pharmaceutical Co. Country or region before: U.S.A. |